New lab work from South Korea identifies microRNA‑93 (miR‑93) as a genetic driver of metabolic‑associated steatotic liver disease (MASLD) and shows that niacin (vitamin B3) strongly suppresses miR‑93 in mice. That makes niacin a promising, low‑cost candidate for repurposing — but human trials and proper dosing guidelines are still needed before changing clinical care.
Who this finding is most relevant to now
The research team from UNIST, Pusan National University and Ulsan University Hospital, working with mouse models, found the clearest benefits in contexts that mirror human MASLD risk: obesity, insulin resistance, and metabolic syndrome. For patients already diagnosed with MASLD (especially with coexisting diabetes or obesity), the study identifies a plausible molecular target — miR‑93 — that therapies could aim at, but it does not establish a ready‑to‑use treatment.
Practically, this is most relevant to clinicians and researchers considering trial design, and to patients following MASLD research: if you are managing MASLD now, continue standard care (weight loss, metabolic control, hepatology follow‑up). If you are a specialist designing a trial, this paper points to niacin as an attractive repurposing candidate because it is already FDA‑approved for other uses and widely available.
How niacin works on miR‑93 and what the preclinical evidence shows
Mechanism and experiments: the team showed miR‑93 levels are abnormally elevated in MASLD models and that miR‑93 suppresses SIRT1, a gene central to healthy lipid metabolism. Reducing miR‑93 in mice — through genetic manipulation — improved liver fat content, lowered inflammation markers, and improved insulin sensitivity; forcing higher miR‑93 had the opposite effect. Separately, a screen of 150 FDA‑approved drugs identified niacin as the single most effective agent at lowering miR‑93 expression in their assays.
In the niacin‑treated mice, researchers reported restoration of SIRT1 activity and normalization of downstream lipid pathways, which matched the benefits seen with direct miR‑93 reduction. Those links — miR‑93 → SIRT1 → lipid metabolism — explain why suppressing miR‑93 could translate to meaningful change in liver biology, but they remain preclinical findings until human studies confirm them.
Evidence status, trade‑offs, and practical checkpoints
A concise comparison helps decide next steps: animal proof of concept exists, the drug is FDA‑approved for other indications, but there are no conclusive human MASLD trials yet. The immediate decision is whether to wait for trial data or consider controlled, clinician‑supervised off‑label use in select patients — most clinicians will prefer waiting for trial results that define dose and safety for MASLD specifically.
| Item | What the paper shows | Practical implication / checkpoint |
|---|---|---|
| miR‑93 role | Elevated in MASLD models; suppresses SIRT1 and worsens liver outcomes | Consider miR‑93 a validated preclinical target; clinics should not use miR tests alone to change therapy yet |
| Niacin effect (preclinical) | Top hit from a screen of 150 FDA‑approved drugs; lowered miR‑93 and restored SIRT1 in mice | Supports repurposing trials; do not assume human efficacy or set doses from mouse data |
| Regulatory and safety context | Niacin is FDA‑approved for dyslipidemia and has an established safety profile in that setting | Next checkpoint: randomized human trials to define MASLD dosing, monitoring, and contraindications |
When to proceed, adjust, avoid, or stop — a clinician‑level decision lens
Proceed only in structured settings: clinicians should consider niacin for MASLD within clinical trials or formal off‑label protocols that include baseline liver tests, regular enzyme monitoring, and clear stopping rules. The paper’s authors emphasize that human studies are the next step; until then, routine prescribing for MASLD outside trials is premature.
Adjust or stop when objective thresholds appear: rising liver enzymes, new or worsening metabolic derangements noted by bloodwork, or clear adverse effects should prompt discontinuation. For trial planners, meaningful checkpoints include predefined liver enzyme cutoffs, standardized doses informed by phase I data, and stratification for patients with diabetes or advanced fibrosis because those groups may respond differently.
Short Q&A
Can I start taking niacin for fatty liver now? Not as a confirmed MASLD therapy. The animal data are promising, but randomized human trials are required to establish effective doses and safety for this indication.
What should make clinicians or patients stop niacin if it’s prescribed in a trial? Prespecified increases in liver enzymes, significant new symptoms, or other protocol‑defined adverse events should trigger stopping rules; trials will set exact thresholds.
When will we know if niacin works in people with MASLD? The next checkpoint is publication of controlled human trials testing niacin specifically for MASLD. The South Korean team has signaled plans for human work and combination‑therapy exploration, but no definitive trial results are available yet.